SARS-CoV-2: Immunoglobulins levels in Infected and Post-Vaccinated Subjects | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 48, Volume 95, Issue 1, April 2024, Page 1596-1600 PDF (364.78 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2024.351021 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: There is currently a lack of clarity on the length and type of immune responses to SARS-CoV-2 infection. The predominant immune response to infection in humans is thought to be due to their presumed lack of immunological experience with SARS-CoV-2. Objective: This study aimed to use IgG and IgM titre of SARS-CoV-2 for vaccine efficacy assessment. Materials and methods: This study was conducted on a cohort of 82 individuals; 41 subjects were positive COVID-19 and 41 subjects taking COVID-19 vaccine in Zagazig, Sharkia. All patients had comprehensive medical histories taken, physical exams performed, and blood samples taken in order to evaluate the following: ELISA-based quantitative serological IgM and IgG levels were measured three weeks following the second dose of the Sinopharm and AstraZeneca vaccines, in addition to a full blood count. Results: The results showed that IgM and IgG were significantly higher among Infected subjects compared to vaccinated subjects. We also noted that there was no significant association between IgM & IgG and age & gender or comorbidities. Regarding side effects, flu symptoms were the most prevalent side effects that were found in 26.8% of the patients, shoulder edema in 14.6% and local irritation in 2.4%. Conclusions:IgG and IgM are good parameters for COVID-19 infection follow up and a significant indictor for vaccination effectiveness for prevention of transmission of SARS-Cov-2. | ||||
| Keywords | ||||
| SARS-CoV-2; COVID-19; COVID-19 vaccine; IgM; and IgG | ||||
|
Statistics Article View: 46 PDF Download: 79 |
||||
